Catabasis Pharma's CAT-1004 Fast Track'd for DMD
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 7:25AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
EMA accepts BioMarin's MAA for drisapersen; marketing clearance possible in Q3 2016
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 3:32PM CDT
CAPR: 4.46 (-0.04), RNA: 18.65 (unch), CATB: 7.66 (-0.10), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Akashi Therapeutics' Duchenne MD candidate shows encouraging results in early stage study
Seeking Alpha - at Seeking Alpha - Thu Jun 18, 9:48AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Catabasis Pharma initiates Phase 1/2 study of DMD candidate
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 9:45AM CDT
CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), CATB: 7.66 (-0.10), SRPT: 37.09 (-0.72), PFE: 33.24 (+0.15), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
FDA publishes draft guidance for firms developing Duchenne muscular dystrophy drugs; current front-runners OK
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 12:07PM CDT
BMRN: 102.69 (+1.97), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28)
Capricor Therapeutics jumps on FDA OK for DMD study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 8:41AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Sarepta to initiate rolling NDA submission for eteplirsen; shares jump 38%
Seeking Alpha - at Seeking Alpha - Tue May 19, 4:40PM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
BioMarin completes rolling NDA submission for drisapersen for DMD
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 9:24AM CDT
ROSG: 2.58 (+0.05), CAPR: 4.46 (-0.04), BMRN: 102.69 (+1.97), RNA: 18.65 (unch), PFE: 33.24 (+0.15), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28), SMMT: 10.35 (+0.12)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 269.16 (-10.72), VRTX: 110.00 (+0.97), PRGO: 160.60 (+2.26), PFE: 33.24 (+0.15), CLDN: 1.12 (+0.03), MYL: 42.55 (-0.12), OREX: 2.53 (+0.15), JNJ: 95.37 (+0.29), NVO: 54.61 (-0.12), TNXP: 6.99 (+0.01), ALNY: 83.16 (+0.88), GILD: 100.65 (-0.16), SGEN: 39.38 (+0.87), ACHN: 7.57 (-0.10), MRK: 50.95 (-0.07), GALE: 1.74 (+0.01), JUNO: 48.64 (+0.84), SNY: 48.75 (+0.03), NBY: 0.32 (unch), XLRN: 24.08 (-0.18)
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 102.69 (+1.97), SRPT: 37.09 (-0.72), PTCT: 34.23 (+2.28)